File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/17474086.2019.1660640
- Scopus: eid_2-s2.0-85071976324
- PMID: 31487202
- WOS: WOS:000485826600001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas
Title | Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas |
---|---|
Authors | |
Keywords | NK/T-cell lymphoma Epstein Barr virus L-asparaginase hematopoietic stem cell transplantation programmed cell death protein 1 |
Issue Date | 2019 |
Publisher | Expert Reviews Ltd. |
Citation | Expert Review of Hematology, 2019, v. 12 n. 11, p. 927-935 How to Cite? |
Abstract | Introduction: Natural killer (NK)/T-cell lymphomas are aggressive malignancies that present predominantly in nasal and adjacent sites (nasal subtype), occasionally in skin, gastrointestinal tract and other tissues (non-nasal), and rarely as disseminated disease with a leukemic phase (aggressive NK-cell leukemia, or leukemia/lymphoma, subtype).
Areas covered: The diagnosis and treatment of NK/T-cell lymphoma are discussed, based on a PubMed literature search. The diagnostic criteria for NK/T-cell lymphoma are highlighted, followed by an update of the diagnostic and prognostic importance (on presentation, at interim and end-of-treatment) of plasma EBV DNA as a surrogate biomarker of lymphoma load. Prognostic models based on clinicopathologic features and EBV DNA load are discussed. For stage I/II NK/T-cell lymphomas, combined chemotherapy, and radiotherapy gives the best results, with their concomitant or sequential administration equally efficacious. For stage III/IV NK/T-cell lymphoma, chemotherapy is the mainstay of treatment. Conventional anthracycline-based regimens for B-cell lymphomas are ineffective. Recommended regimens combine L-asparaginase with other drugs not affected by P-glycoprotein. For relapsed/refractory patients, immune checkpoint blockade with antibodies against programmed cell death protein 1 has shown much promise.
Expert opinion: Current strategies result in durable remissions in a significant proportion of NK/T-cell lymphomas. Immune checkpoint inhibition and other novel approaches are promising for relapsed/refractory cases.
KEYWORDS: |
Persistent Identifier | http://hdl.handle.net/10722/281806 |
ISSN | 2023 Impact Factor: 2.3 2023 SCImago Journal Rankings: 0.699 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tse, E | - |
dc.contributor.author | Au-Yeung, R | - |
dc.contributor.author | Kwong, Y-L | - |
dc.date.accessioned | 2020-03-27T04:22:44Z | - |
dc.date.available | 2020-03-27T04:22:44Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Expert Review of Hematology, 2019, v. 12 n. 11, p. 927-935 | - |
dc.identifier.issn | 1747-4086 | - |
dc.identifier.uri | http://hdl.handle.net/10722/281806 | - |
dc.description.abstract | Introduction: Natural killer (NK)/T-cell lymphomas are aggressive malignancies that present predominantly in nasal and adjacent sites (nasal subtype), occasionally in skin, gastrointestinal tract and other tissues (non-nasal), and rarely as disseminated disease with a leukemic phase (aggressive NK-cell leukemia, or leukemia/lymphoma, subtype). Areas covered: The diagnosis and treatment of NK/T-cell lymphoma are discussed, based on a PubMed literature search. The diagnostic criteria for NK/T-cell lymphoma are highlighted, followed by an update of the diagnostic and prognostic importance (on presentation, at interim and end-of-treatment) of plasma EBV DNA as a surrogate biomarker of lymphoma load. Prognostic models based on clinicopathologic features and EBV DNA load are discussed. For stage I/II NK/T-cell lymphomas, combined chemotherapy, and radiotherapy gives the best results, with their concomitant or sequential administration equally efficacious. For stage III/IV NK/T-cell lymphoma, chemotherapy is the mainstay of treatment. Conventional anthracycline-based regimens for B-cell lymphomas are ineffective. Recommended regimens combine L-asparaginase with other drugs not affected by P-glycoprotein. For relapsed/refractory patients, immune checkpoint blockade with antibodies against programmed cell death protein 1 has shown much promise. Expert opinion: Current strategies result in durable remissions in a significant proportion of NK/T-cell lymphomas. Immune checkpoint inhibition and other novel approaches are promising for relapsed/refractory cases. KEYWORDS: | - |
dc.language | eng | - |
dc.publisher | Expert Reviews Ltd. | - |
dc.relation.ispartof | Expert Review of Hematology | - |
dc.rights | Expert Review of Hematology. Copyright © Expert Reviews Ltd. | - |
dc.subject | NK/T-cell lymphoma | - |
dc.subject | Epstein Barr virus | - |
dc.subject | L-asparaginase | - |
dc.subject | hematopoietic stem cell transplantation | - |
dc.subject | programmed cell death protein 1 | - |
dc.title | Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas | - |
dc.type | Article | - |
dc.identifier.email | Tse, E: ewctse@hku.hk | - |
dc.identifier.email | Au-Yeung, R: rex.auyeung@hku.hk | - |
dc.identifier.email | Kwong, Y-L: ylkwong@hkucc.hku.hk | - |
dc.identifier.authority | Tse, E=rp00471 | - |
dc.identifier.authority | Au-Yeung, R=rp01877 | - |
dc.identifier.authority | Kwong, Y-L=rp00358 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1080/17474086.2019.1660640 | - |
dc.identifier.pmid | 31487202 | - |
dc.identifier.scopus | eid_2-s2.0-85071976324 | - |
dc.identifier.hkuros | 309561 | - |
dc.identifier.volume | 12 | - |
dc.identifier.issue | 11 | - |
dc.identifier.spage | 927 | - |
dc.identifier.epage | 935 | - |
dc.identifier.isi | WOS:000485826600001 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1747-4094 | - |